Hope S Rugo1, Abhijit Barve2, Cornelius F Waller3, Miguel Hernandez-Bronchud4, Jay Herson5, Jinyu Yuan6, Rajiv Sharma6, Mark Baczkowski6, Mudgal Kothekar7, Subramanian Loganathan7, Alexey Manikhas8, Igor Bondarenko9, Guzel Mukhametshina10, Gia Nemsadze11, Joseph D Parra12, Maria Luisa T Abesamis-Tiambeng13, Kakhaber Baramidze14, Charuwan Akewanlop15, Ihor Vynnychenko16, Virote Sriuranpong17, Gopichand Mamillapalli18, Sirshendu Ray19, Eduardo P Yanez Ruiz20, Eduardo Pennella6. 1. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco. 2. Biocon Research Limited, Bangalore, India3Now with Mylan Inc, Canonsburg, Pennsylvania. 3. Department of Haematology, Oncology, and Stem Cell Transplantation, University Medical Centre Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany. 4. Quiron-Dexeus, Barcelona, Spain. 5. Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 6. Mylan Inc, Canonsburg, Pennsylvania. 7. Biocon Research Limited, Bangalore, India. 8. City Clinical Oncology Dispensary, Saint Petersburg, Russia. 9. Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine. 10. Regional Clinical Oncological Center, Kazan, Russia. 11. Institute of Clinical Oncology, Tbilisi, Georgia. 12. St Luke's Medical Center Global City, Taguig City, Philippines. 13. Cardinal Santos Medical Center, Manila, Philippines. 14. Golden Fleece 21 Century Health House Ltd, Tbilisi, Georgia. 15. Siriraj Hospital, Bangkok, Thailand. 16. Sumy State University, Sumy, Ukraine. 17. King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand. 18. City Cancer Center, Vijayawada, India. 19. Curie Manavata Cancer Centre, Nasik, India. 20. Instituto Clinico Oncologico del Sur, Temuco, Chile.
Abstract
Importance: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. Objective: To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positive metastatic breast cancer. Design, Setting, and Participants: Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. Interventions: Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. Main Outcomes and Measures: The primary outcome was week 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to 15% with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. Results: Among 500 women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493 women. The ORR was 69.6% (95% CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0% (95% CI, 57.81%-70.26%) for trastuzumab. The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were within the equivalence boundaries. At week 48, there was no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3% vs 43.0%; -1.7%; 95% CI, -11.1% to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95% CI, -9.4% to 8.7%), or overall survival (89.1% vs 85.1%; 4.0%; 95% CI, -2.1% to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.1% vs 24.8%), and diarrhea (20.6% vs 20.7%). Conclusions and Relevance: Among women with ERBB2-positive metastatic breast cancer receivingtaxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome. Trial Registration: clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier: 2011-001965-42.
RCT Entities:
Importance: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. Objective: To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positive metastatic breast cancer. Design, Setting, and Participants: Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. Interventions: Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. Main Outcomes and Measures: The primary outcome was week 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to 15% with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. Results: Among 500 women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493 women. The ORR was 69.6% (95% CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0% (95% CI, 57.81%-70.26%) for trastuzumab. The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were within the equivalence boundaries. At week 48, there was no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3% vs 43.0%; -1.7%; 95% CI, -11.1% to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95% CI, -9.4% to 8.7%), or overall survival (89.1% vs 85.1%; 4.0%; 95% CI, -2.1% to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.1% vs 24.8%), and diarrhea (20.6% vs 20.7%). Conclusions and Relevance: Among women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome. Trial Registration: clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier: 2011-001965-42.
Authors: Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke Journal: Drugs Date: 2017-08 Impact factor: 9.546
Authors: Pier Luigi Zinzani; Martin Dreyling; William Gradishar; Marc Andre; Francisco J Esteva; Suliman Boulos; Eva González Barca; Giuseppe Curigliano Journal: Drugs Date: 2019-10 Impact factor: 9.546
Authors: Bo Huang; Lu Tian; Zachary R McCaw; Xiaodong Luo; Enayet Talukder; Mace Rothenberg; Wanling Xie; Toni K Choueiri; Dae Hyun Kim; Lee-Jen Wei Journal: Ann Intern Med Date: 2020-07-07 Impact factor: 25.391
Authors: Victoria M Youngblood; Ruth Nyirenda; Richard Nyasosela; Takondwa Zuze; Yi Yang; Evaristar Kudowa; Agnes Moses; Jennifer Kincaid; Chifundo Kajombo; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Chrissie Chilima; Grace K Ellis; Ryan Seguin; Maganizo Chagomerana; Rebecca Maine; Sheryl Jordan; Anthony Charles; Clara Lee; Satish Gopal; Tamiwe Tomoka Journal: Cancer Causes Control Date: 2020-03-02 Impact factor: 2.506